haematology
Blood cancers

Have confidence in biosimilars in haematology: consensus statement

Haematologists can have confidence in the equivalence of biosimilar products to the original reference molecule when it comes to efficacy, safety and when switching between products, a new Australian consensus statement advises. With the emergence of biosimilar brands for biologic agents used in haematology such as rituximab, clinicians and patients need to be informed and ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic